Oral Semaglutide's Gut Side Effects: What GLP-1 Users Should Know

A newly published peer-reviewed study in the Journal of Controlled Release suggests that the absorption-enhancing ingredient used to make oral semaglutide work — not just the drug itself — may be contributing to the gut side effects that cause many patients to stop treatment. For the millions taking or considering oral semaglutide (sold as Rybelsus), the findings offer important new context.

What the Research Found

Oral semaglutide relies on an ingredient called salcaprozate sodium, commonly known as SNAC, to help the drug pass through the stomach lining and reach the bloodstream. Because semaglutide is a large peptide molecule, it cannot be absorbed on its own in pill form — SNAC is what makes oral delivery possible at all.

The new study examined the effects of semaglutide (at a dose of 0.74 mg/kg/day) and SNAC separately and together, focusing on what happens in the gut. Researchers found that SNAC-enabled oral semaglutide delivery was associated with gut microbiota perturbation — meaning disruption to the community of bacteria living in the digestive tract — as well as systemic inflammation. The study noted that oral semaglutide achieves only 0.4–1% bioavailability through gastric epithelial uptake, meaning the vast majority of the drug never reaches circulation, while the gut lining is still exposed to the full dose.

Why Gut Side Effects Matter for Patients

Gastrointestinal adverse events — including nausea, vomiting, diarrhea, and stomach discomfort — are already among the most commonly reported complaints with GLP-1 receptor agonist medications. According to the study abstract, these GI side effects remain a major cause of therapy discontinuation among people taking oral semaglutide.

This research raises the possibility that some of those side effects may trace back to how SNAC interacts with gut bacteria and the intestinal environment, rather than solely to semaglutide's effects on appetite and digestion. That distinction could matter for how doctors and patients manage tolerability in the future.

What This Means If You Take Oral Semaglutide

This is early-stage research, and the study findings do not mean patients should stop their medication without speaking to a doctor. However, the results do suggest a few practical considerations:

• If you're experiencing persistent GI side effects on oral semaglutide, this research supports the idea that your symptoms are real and may have a biological mechanism worth discussing with your prescriber.
• Injectable semaglutide formulations (Ozempic, Wegovy) do not use SNAC, so this specific concern applies only to the oral pill form.
• Patients struggling with tolerability may have options, including switching to an injectable formulation or adjusting their dose — conversations best had with a healthcare provider.

What to Watch Next

This study adds to a growing body of research examining how GLP-1 medications interact with the gut microbiome. Future studies are likely to explore whether the microbiome disruption observed is reversible, whether it differs across patient populations, and whether reformulating oral semaglutide delivery could reduce these effects. Patients and clinicians should watch for follow-up research and any updated clinical guidance on managing GI side effects with oral GLP-1 therapies.

Frequently Asked Questions

As with any change to your medication or concerns about side effects, speak with your prescriber or pharmacist before making decisions. They can help you weigh the benefits and risks of oral semaglutide based on your personal health history and treatment goals.